Give me 'Section 4. Upon the first [ * ]. U.S. ... ' for this agreement: [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Exhibit 10.11 COLLABORATION AGREEMENT
BY AND BETWEEN
ASTELLAS PHARMA INC.
AND
FIBROGEN, INC. June 1, 2005
CONFIDENTIAL EXECUTION COPY TABLE OF CONTENTS ARTICLE 1 DEFINITIONS 1
1.1 "Actions" 1 1.2 "Affiliate" 1 1.3 "Astellas Indemnitees" 1 1.4 "Astellas Territory" 1 1.5 "Authorized Designee" 1 1.6 "Bridging Strategy" 1 1.7 "Bulk Product" 2 1.8 "Commercialize" 2 1.9 "Completion" 2 1.10 "Confidential Information" 2 1.11 "Control" or "Controlled" 2 1.12 "Controlling Party" 2 1.13 "Data" 2 1.14 "Delivery" or "Delivered" 2 1.15 "Development Plan" 2 1.16 "Development Program" 2 1.17 "Enforcement Action" 2 1.18 "Event" 2 1.19 "Expanded Field" 2 1.20 "Expenses" 2 1.21 "FDA" 2 1.22 "FG Acquired Patents" 3 1.23 "FG Development Program" 3 1.24 "FG Indemnitees" 3 1.25 "FG Technology" 3 1.26 "FG Patents" 3 1.27 "FG Technical Information" 3 1.28 "FG Territory" 3 1.29 "Field" 4 1.30 "First Commercial Sale" 4 1.31 "Force Majeure Event" 4 1.32 "Fully Burdened Costs" 4 1.33 "Future Third Party Intellectual Property" 4 1.34 "GMP Guidelines" 4 1.35 "[ * ]" 4 1.36 "[ * ] Percentage" 5 1.37 "HIF" 5 -i-
[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
TABLE OF CONTENTS (continued) Page 1.38 "IND" 5 1.39 "Indemnitee" 5 1.40 "Indemnitor" 5 1.41 "Indications" 5 1.42 "Initial Development Plan" 5 1.43 "Initiate" or Initiation" 5 1.44 "Inspected Party" and "Inspecting Party" 5 1.45 "Joint Development Committee" or "JDC" 5 1.46 "Lead Compound" 5 1.47 "Listed Price" 5 1.48 "Litigation Agreement" 5 1.49 "Major Indication" 6 1.50 "Marketing Approval" 6 1.51 "Marketing Approval Application" or "MAA" 6 1.52 "Net Sales" 6 1.53 "Phase I" 6 1.54 "Phase II" 6 1.55 "Phase III" 6 1.56 "Product Specification" 7 1.57 "Preexisting Third Party Intellectual Property" 7 1.58 "Proof of Concept" 7 1.59 "Prosecution and Interference Activities" 7 1.60 "Protected Field" 7 1.61 "Reference Materials" 7 1.62 "Relevant Standards" 7 1.63 "Sales Price" 7 1.64 "Standard Materials" 7 1.65 "Sublicensee" 8 1.66 "Technical Product Failure" 8 1.67 "Third Party Agreements" 8 1.68 "Third Party Licensor" 8
ARTICLE 2 JOINT DEVELOPMENT COMMITTEE 8